<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377505</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-ECP-2013-20</org_study_id>
    <secondary_id>PI12/00042</secondary_id>
    <nct_id>NCT02377505</nct_id>
  </id_info>
  <brief_title>Deep Brain Stimulation in Treatment Resistant Schizophrenia</brief_title>
  <acronym>DBS-SCHIZO</acronym>
  <official_title>Deep Brain Stimulation in Treatment Resistant Schizophrenia: Randomized, Controlled, Crossover Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondo de Investigacion Sanitaria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at assessing efficacy and safety of Deep Brain Stimulation (DBS) for
      treatment of patients with treatment resistant schizophrenia, by means of a random,
      controlled and crossed study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first phase of the study will consist of implanting electrodes. Recruited patients will
      be random to 2 targets: (1) medial prefrontal cortex (mPFC); (2) nucleus accumbens (NAcc).
      Continuous stimulation will be applied until the patients stabilise clinically. This period
      is anticipated between 6 and 9 months.

      After this stage, the next phase will consist of the crossover study. Those patients who
      respond to DBS will be randomly distributed in two groups, for a period of 3 months: on
      stimulation group and off stimulation group. Patients will then be crossed over to the other
      group for a further 3 months.

      Weekly visits during first month after, and fortnightly visits will be made during the entire
      study to evaluate treatment efficacy and patient tolerance.

      Patients who complete the study and respond to treatment with DBS will be provided continuing
      with treatment, and keeping control visits to assess the long-term effectiveness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">December 23, 2019</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale for Schizophrenia (PANSS)</measure>
    <time_frame>Changes from baseline score to 1-3 weeks scores and to fortnightly scores until the end of trial (12 months)</time_frame>
    <description>Scale to assess changes in schizophrenia' symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Schizophrenia (CGI-SCH)</measure>
    <time_frame>Changes from baseline score to 1-12 months scores</time_frame>
    <description>Scale to assess changes in schizophrenia symptoms' severity, global improvement or change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Functioning Scale (GFS)</measure>
    <time_frame>Changes from baseline score to 1-3 weeks scores and to 1-12 months scores</time_frame>
    <description>Scale to assess changes in social, occupational, and psychological functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Functioning Scale (SFS)</measure>
    <time_frame>Changes from baseline score to 1-3 weeks scores and to 1-12 months scores</time_frame>
    <description>Scale to assess changes in social functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Personal and Social Performance (PSP)</measure>
    <time_frame>Changes from baseline score to 1-12 months scores</time_frame>
    <description>Scale to assess changes in functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychotic Symptom Rating Scales (PSYRATS)</measure>
    <time_frame>Changes from baseline score to 1-12 months scores</time_frame>
    <description>Scale to assess changes in hallucinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scale for the Assessment of Negative Symptoms (SANS)</measure>
    <time_frame>Changes from baseline score to 1-12 months scores</time_frame>
    <description>Scale to assess changes in negative symptoms of schizophrenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calgary Depression Scale for Schizophrenia (CDSS)</measure>
    <time_frame>Changes from baseline score to 1-12 months scores</time_frame>
    <description>Scale to assess changes in depressive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance-Based Skills Assessment (UPSA)</measure>
    <time_frame>Changes from baseline score to 12 months score</time_frame>
    <description>Scale to assess changes in functional capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Assessment</measure>
    <time_frame>Changes from baseline score to 12 months score</time_frame>
    <description>Battery of neuropsychological tests to assess changes in cognition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral metabolism (PET scans)</measure>
    <time_frame>Changes from baseline scan to 6 and 12 months scans</time_frame>
    <description>Assessment of changes in brain blow flow using the nuclear medicine procedure, PET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>n-Back (fMRI scan)</measure>
    <time_frame>Changes from baseline scan to 6 and 12 months scans</time_frame>
    <description>Task to measure changes in working memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Changes from baseline score to 1-3 weeks scores and to fortnightly scores until the end of trial (12 months)</time_frame>
    <description>All unexpected medical problem that happens during DBS treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Refractory Schizophrenia</condition>
  <arm_group>
    <arm_group_label>On-Stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Disease condition is assessed with stimulation turned &quot;on&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Off-Stimulation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Disease condition is assessed with stimulation turned &quot;off&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>On-Stimulation</intervention_name>
    <description>The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is &quot;on&quot;</description>
    <arm_group_label>On-Stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Off-Stimulation</intervention_name>
    <description>The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is &quot;off&quot;</description>
    <arm_group_label>Off-Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged between 18 and 55 years.

          2. DSM IV-TR diagnosis of schizophrenia for at least 3 years prior to the screening
             visit.

          3. Determined to be treatment-resistant as demonstrated by:

               1. Persistence of positive symptoms which have not responded to appropriate
                  treatments for at least 2 years.

               2. Inadequate response from adequate trials of two different classes of
                  antipsychotic drugs (not including clozapine), at least 8 weeks.

               3. Inadequate response from adequate trial of clozapine, at least 3 months, or
                  unable to tolerate clozapine because of intolerable side effects.

               4. ECT is contraindicated or have failed to produce a maintained response.

          4. Persistence of positive symptoms defined as i) requiring a score of 4 (mild) or more
             on at least 2 of the next PANSS items: delusions, hallucinatory behavior,
             suspiciousness and unusual thought content; or as ii) requiring a score of 6 (severe)
             or more on at least 1 of the above PANSS items.

          5. Current CGI score 6 or more

          6. Stable antipsychotic treatment for last 2 months.

          7. Women of childbearing age using medically approved contraceptive methods.

          8. Adequate familiar or social support during all study procedures.

        Exclusion Criteria:

          1. MRI (Magnetic Resonance Imaging) contraindication to stimulation or contraindications
             for MRI

          2. History of epilepsy or clozapine-induced seizures, where use of anticonvulsants was
             needed

          3. Current suicidal ideation, plan or intent for self-harm during last 2 months.

          4. Evidence of global cognitive impairment.

          5. Current acute, serious or unstable illnesses.

          6. History of substance abuse (other than tobacco or caffeine).

          7. Comorbid axis I or II DSM IV-TR disorders.

          8. Female patients who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iluminada Corripio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry. Hospital Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FIDMAG Germanes Hospitalàries Research Foundation</name>
      <address>
        <city>Sant Boi de Llobregat</city>
        <state>Barcelona</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry. Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Salgado-López L, Pomarol-Clotet E, Roldán A, Rodríguez R, Molet J, Sarró S, Álvarez E, Corripio I. Letter to the Editor: Deep brain stimulation for schizophrenia. J Neurosurg. 2016 Jul;125(1):229-30. doi: 10.3171/2015.12.JNS152874. Epub 2016 Apr 22.</citation>
    <PMID>27104842</PMID>
  </results_reference>
  <results_reference>
    <citation>Corripio I, Sarró S, McKenna PJ, Molet J, Álvarez E, Pomarol-Clotet E, Portella MJ. Clinical Improvement in a Treatment-Resistant Patient With Schizophrenia Treated With Deep Brain Stimulation. Biol Psychiatry. 2016 Oct 15;80(8):e69-70. doi: 10.1016/j.biopsych.2016.03.1049. Epub 2016 Mar 10.</citation>
    <PMID>27113497</PMID>
  </results_reference>
  <results_reference>
    <citation>Corripio I, Roldán A, Sarró S, McKenna PJ, Alonso-Solís A, Rabella M, Díaz A, Puigdemont D, Pérez-Solà V, Álvarez E, Arévalo A, Padilla PP, Ruiz-Idiago JM, Rodríguez R, Molet J, Pomarol-Clotet E, Portella MJ. Deep brain stimulation in treatment resistant schizophrenia: A pilot randomized cross-over clinical trial. EBioMedicine. 2020 Jan;51:102568. doi: 10.1016/j.ebiom.2019.11.029. Epub 2020 Jan 8.</citation>
    <PMID>31927311</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment-Resistant Schizophrenia</keyword>
  <keyword>Deep Brain Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

